The Abl oncogene was initially identified as the viral transforming gene of Abelson murine leukemia virus (A-MuLV). The major translational product of c-Abl has been identified as a protein with tyrosine kinase activity and an SH2 domain. The Abl oncogene is implicated in several human leukemias including chronic myelocytic leukemia (CML), in which it undergoes a (9;22) chromosomal translocation and produces the Philadelphia (Ph1) chromosome. The molecular consequence of this translocation is the generation of a chimeric Bcr/c-Abl mRNA encoding activated Abl protein tyrosine kinase. The related protein tyrosine kinase Arg, also designated Abl2, contains an SH2 and an SH3 domain. Arg has been shown to interact with and to phosphorylate c-Crk.
Fig1: Western blot analysis of ABL2 on different lysates using anti-ABL2 antibody at 1/1,000 dilution. Positive control: Lane 1: Hela Lane 2: PC-12 Lane 3: Jurkat
Application
Fig2: Flow cytometric analysis of Raji cells with ABL2 antibody at 1/50 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black). Alexa Fluor 488-conjugated goat anti rabbit IgG was used as the secondary antibody
Positive Control
PC-12, Jurakt, Hela.
Application Notes
WB:1:1,000-1:2,000 FC:1:50-1:100
Additional Information
Form
Liquid
Storage Instructions
Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles.
